BioTech: In the final stretch for the vaccine – The co-founders in the 100 richest Germans

As early as September, Ugur Sahin, co-founder and head of Biontech, which is already one of the 100 richest people in Germany, had high hopes for developing a highly effective coronavirus vaccine. Now his company has announced that the vaccine offers 90% protection against the virus. If the vaccine prevails, this would also be good news for many thousands of Biontech shareholders. Its share price has already tripled since March. The young company’s capitalization has exceeded the $ 20 billion mark, so Biontech is now worth three to four times more than Lufthansa or Commerzbank. This, in turn, should also thank Ugur Sahin and his wife. owner, Dr. Ozlem Touretzi, as both are not only extremely successful medical researchers, but are also now billionaires. The two founders of Biontech still hold 18% of the share capital. With the spectacular success of their company, they suddenly emerged as the 100 richest Germans. The success is not only evident in the stock market, as many countries also want to supply the vaccine in sufficient quantities for their citizens. The promising Biontech and American Pfizer vaccine will soon be available in the European Union as well. At the age of four, Sahin and his mother moved from Turkey to his father, who worked at the Ford plant in Cologne. After graduating from high school, he studied medicine at the University of Cologne, where he also received his doctorate. His specialty is in immunology and cancer research. In 2008, Sahin co-founded the biotechnology company BionTech in Mainz with Ozlem Touretzi, of which he has been the CEO since April 2020. He and his team have been researching a coronavirus vaccine since The pharmaceutical company announced that the newly developed vaccine BNT162b2 is so successful that it will start mass production on the one hand and on the other hand has submitted an application for the final approval process. It is just before the “end of the coronavirus pandemic”. The fact that a vaccine will be available a few months after the pandemic breaks out is a scientific achievement. It usually takes several years to develop and approve vaccines. However, whether millions of vaccine doses will actually be given this year depends on the European Medicines Agency (EMA) and its rapid approval. “In any case, we will submit the our data and we will present transparently the action and the side effects. “Vaccine doses will also be available,” said Biontech chief executive and co-founder Ugur Sahin of the Frankfurter Allgemeine Zeitung. in order to be able to increase mass production quickly. Soon one of the largest coronavirus vaccine production facilities in the world could be built there. Biontech is planning 100 million doses of vaccine this year and 250 million in the first half of 2021. In the coming years, production will increase to 750 million a year. News from Greece and the World, at

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *